| Name | Title | Contact Details |
|---|
A publicly traded (OTC: CBSC) company providing innovative products and services in the ambulatory non-invasive cardiac monitoring space. CB Scientific, Inc., through its US and international subsidiaries, provides innovative products and services in the ambulatory non-invasive cardiac monitoring space. Our FDA and CE cleared EKG devices, interactive cloud-based acquisition software, and smartphone apps for both iOS and Android platforms, provide improved compliance for patients at risk of abnormal heart rhythms as well as more accurate information for physicians.
GT Urological is a Minneapolis, MN-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Instromedix dba: LifeWatch is a Des Plaines, IL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
BD is one of the largest global medical technology companies in the world and is advancing the world of health by improving medical discovery` diagnostics and the delivery of care. The company supports the heroes on the frontlines of health care by developing innovative technology` services and solutions that help advance both clinical therapy for patients and clinical process for health care providers. BD and its 65`000 employees have a passion and commitment to help improve patient outcomes` improve the safety and efficiency of clinicians` care delivery process` enable laboratory scientists to better diagnose disease and advance researchers’ capabilities to develop the next generation of diagnostics and therapeutics. BD has a presence in virtually every country and partners with organizations around the world to address some of the most challenging global health issues. By working in close collaboration with customers` BD can help enhance outcomes` lower costs` increase efficiencies` improve safety and expand access to health care. In 2017` BD welcomed C. R. Bard and its products into the BD family.
The Miromatrix Medical technology has the potential to enable the creation of fully biological replacement organs for the human body. In addition to the Company’s internal efforts focused on the development of its first product – a biological mesh for hernia repair – scientists around the globe are working with the Company’s technology and are taking critical steps toward the creation of human organs including the liver, lung, kidney, pancreas and heart. While our biological mesh development program has been conducted internally, our intent is for current and future products to be developed both at Miromatrix and in partnership with the best among those external groups already working with our technology in order to utilize this pre-existing expertise to develop individual products in the most efficacious, cost-effective and timely way possible.